2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-01,Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2017-02-28,Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis
2017-02-27,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2017-02-10,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
2017-02-10,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2017-02-08,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity
2017-02-07,Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Alnylam Presents New Data On Fitusiran At EAHAD
2017-02-01,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-03,Alnylam Announces Management Change And Key Promotion
2017-01-03,Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-16,Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy
2016-12-08,Alnylam To Webcast R&D Day
2016-12-05,Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2016-12-04,Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors
2016-12-03,Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors
2016-12-03,Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-14,Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders
2016-11-13,Http://www.themedicinescompany.com/
2016-11-03,Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)
2016-11-02,Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity
2016-10-31,Alnylam To Webcast Presentations At Upcoming November Investor Conferences
2016-10-28,Lifshitz & Miller Law Firm Announces Investigation Of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, Inc., And Supreme Industries Inc.
2016-10-26,Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results
2016-10-10,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation
2016-10-10,Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-10-07,Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades
2016-10-07,Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More
2016-10-06,Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report
2016-10-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)
2016-10-06,Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development
2016-10-06,Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report
2016-10-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors
2016-10-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY
2016-10-06,Stocks Extend Declines as Twitter Shares Sag
2016-10-06,Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded
2016-10-06,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector
2016-10-06,Stock Futures Edge Lower as Jobless Claims Fall
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-10-05,Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development
2016-10-05,Alnylam Pharmaceuticals Discontinues Revusiran Development
2016-10-03,Alnylam Commemorates 10th Anniversary Of The Nobel Prize In Physiology Or Medicine Awarded For The Discovery Of RNAi
2016-09-28,Alnylam Presents Clinical And Non-Clinical Data Demonstrating Continued RNAi Platform Optimization And Leadership In The Development Of RNA-Based Therapeutics At 12th Annual Meeting Of The Oligonucleotide Therapeutics Society
2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
2016-09-21,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Operating Officer
2016-09-19,Alnylam Expands And Strengthens Management Team As It Plans For Commercialization
2016-09-07,Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AS1, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-09-06,Alnylam To Webcast Presentations At Upcoming September Investor Conferences
2016-08-08,Alnylam Completes Enrollment In ENDEAVOUR Phase 3 Study With Revusiran, An Investigational RNAi Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (hATTR-CM)
2016-08-04,Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-08-02,Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference
2016-08-02,Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-28,Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results
2016-07-25,Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders
2016-07-25,Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-25,Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-15,5 Toxic Stocks to Sell as Anxiety Creeps Higher
2016-07-12,Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series
2016-07-07,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection
2016-07-01,Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
2016-07-01,Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)
2016-06-29,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2016-06-27,Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis
2016-06-27,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-25,'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
2016-06-11,Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study
2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
2016-06-06,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2016-06-03,Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal
2016-06-03,Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
2016-05-31,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2016-05-27,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-16,Strong On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-05-12,Insiders Now Seeing Red With ALNY At New 52-Week Low
2016-05-12,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock
2016-05-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock
2016-05-02,Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-04-28,Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)
2016-04-26,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2016-04-25,Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results
2016-04-20,Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-04-07,Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today
2016-04-06,Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference
2016-04-03,Somber Sentiment Makes Me Wonder
2016-03-14,Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,3 Stocks Pulling The Drugs Industry Downward
2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2016-02-29,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2016-02-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2016-02-11,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress
2016-02-04,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results
2016-02-01,Alnylam To Webcast Presentations At Upcoming February Investor Conferences
2016-02-01,Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2016-01-27,Weak On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-01-14,Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock
2016-01-11,Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline
2016-01-04,Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference
2015-12-29,Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-12-18,Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage
2015-12-17,Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5
2015-12-10,Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day
2015-12-08,Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
2015-12-07,Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B
2015-12-06,Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen
2015-12-03,3 Drugs Stocks Moving The Industry Upward
2015-12-02,Alnylam To Webcast R&D Day
2015-11-23,Alnylam To Webcast Presentations At Upcoming December Investor Conferences
2015-11-13,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-09,Alnylam (ALNY) Stock Climbs Following Earnings Release
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period
2015-11-05,Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)
2015-11-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock
2015-11-03,Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-11-02,Alnylam To Webcast Presentations At Upcoming November Conferences
2015-11-02,Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results
2015-10-29,Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis
2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
2015-10-13,Alnylam Advances New Innovations In RNAi Therapeutics
2015-10-08,Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-10-07,Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock
2015-10-01,Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe
2015-09-28,Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute
2015-09-28,Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-09-25,Alnylam Pharmaceuticals Becomes Oversold
2015-09-21,Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)
2015-09-15,Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias
2015-09-10,Alnylam To Webcast Presentations At Upcoming September Conferences
2015-09-09,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today
2015-08-30,(Graphic: Business Wire)
2015-08-21,Ratings Changes Today
2015-08-07,Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-06,Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)
2015-08-06,Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities
2015-08-05,Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results
2015-07-30,3 Stocks Pushing The Drugs Industry Downward
2015-07-27,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-07-20,Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
2015-07-17,Today's Stocks Driving Success For The Drugs Industry
2015-07-17,Faruqi & Faruqi, LLP Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) On Behalf Of Its Shareholders
2015-07-16,Alnylam To Reschedule First RNAi Roundtable Webcast
2015-07-06,Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series
2015-06-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2015-06-23,Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-06-12,Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today
2015-06-12,Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases
2015-06-10,Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
2015-06-08,Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
2015-06-05,Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2015-05-28,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2015-05-26,Ratings Changes Today
2015-05-26,4 Big Biotech Companies to Sell Now
2015-05-26,Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
2015-05-20,Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-05-17,Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-05-15,3 Health Care Stocks Nudging The Sector Higher
2015-05-07,Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings
2015-05-07,Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress
2015-05-07,Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva
2015-04-30,Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results
2015-04-29,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2015-04-21,Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-04-16,New Lifetime High For Alnylam Pharmaceuticals (ALNY)
2015-04-13,Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-01,Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2017-02-28,Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis
2017-02-27,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2017-02-10,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
2017-02-10,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2017-02-08,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity
2017-02-07,Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Alnylam Presents New Data On Fitusiran At EAHAD
2017-02-01,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-03,Alnylam Announces Management Change And Key Promotion
2017-01-03,Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-16,Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy
2016-12-08,Alnylam To Webcast R&D Day
2016-12-05,Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2016-12-04,Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors
2016-12-03,Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors
2016-12-03,Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-14,Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders
2016-11-13,Http://www.themedicinescompany.com/
2016-11-03,Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)
2016-11-02,Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity
2016-10-31,Alnylam To Webcast Presentations At Upcoming November Investor Conferences
2016-10-28,Lifshitz & Miller Law Firm Announces Investigation Of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, Inc., And Supreme Industries Inc.
2016-10-26,Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results
2016-10-10,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation
2016-10-10,Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-10-07,Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades
2016-10-07,Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More
2016-10-06,Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report
2016-10-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)
2016-10-06,Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development
2016-10-06,Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report
2016-10-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors
2016-10-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY
2016-10-06,Stocks Extend Declines as Twitter Shares Sag
2016-10-06,Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded
2016-10-06,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector
2016-10-06,Stock Futures Edge Lower as Jobless Claims Fall
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-10-05,Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development
2016-10-05,Alnylam Pharmaceuticals Discontinues Revusiran Development
2016-10-03,Alnylam Commemorates 10th Anniversary Of The Nobel Prize In Physiology Or Medicine Awarded For The Discovery Of RNAi
2016-09-28,Alnylam Presents Clinical And Non-Clinical Data Demonstrating Continued RNAi Platform Optimization And Leadership In The Development Of RNA-Based Therapeutics At 12th Annual Meeting Of The Oligonucleotide Therapeutics Society
2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
2016-09-21,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Operating Officer
2016-09-19,Alnylam Expands And Strengthens Management Team As It Plans For Commercialization
2016-09-07,Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AS1, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-09-06,Alnylam To Webcast Presentations At Upcoming September Investor Conferences
2016-08-08,Alnylam Completes Enrollment In ENDEAVOUR Phase 3 Study With Revusiran, An Investigational RNAi Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (hATTR-CM)
2016-08-04,Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-08-02,Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference
2016-08-02,Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-28,Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results
2016-07-25,Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders
2016-07-25,Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-25,Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-15,5 Toxic Stocks to Sell as Anxiety Creeps Higher
2016-07-12,Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series
2016-07-07,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection
2016-07-01,Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
2016-07-01,Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)
2016-06-29,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2016-06-27,Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis
2016-06-27,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-25,'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
2016-06-11,Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study
2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
2016-06-06,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2016-06-03,Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal
2016-06-03,Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
2016-05-31,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2016-05-27,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-16,Strong On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-05-12,Insiders Now Seeing Red With ALNY At New 52-Week Low
2016-05-12,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock
2016-05-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock
2016-05-02,Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-04-28,Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)
2016-04-26,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2016-04-25,Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results
2016-04-20,Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-04-07,Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today
2016-04-06,Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference
2016-04-03,Somber Sentiment Makes Me Wonder
2016-03-14,Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,3 Stocks Pulling The Drugs Industry Downward
2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2016-02-29,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2016-02-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2016-02-11,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress
2016-02-04,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results
2016-02-01,Alnylam To Webcast Presentations At Upcoming February Investor Conferences
2016-02-01,Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2016-01-27,Weak On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-01-14,Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock
2016-01-11,Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline
2016-01-04,Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference
2015-12-29,Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-12-18,Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage
2015-12-17,Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5
2015-12-10,Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day
2015-12-08,Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
2015-12-07,Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B
2015-12-06,Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen
2015-12-03,3 Drugs Stocks Moving The Industry Upward
2015-12-02,Alnylam To Webcast R&D Day
2015-11-23,Alnylam To Webcast Presentations At Upcoming December Investor Conferences
2015-11-13,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-09,Alnylam (ALNY) Stock Climbs Following Earnings Release
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period
2015-11-05,Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)
2015-11-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock
2015-11-03,Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-11-02,Alnylam To Webcast Presentations At Upcoming November Conferences
2015-11-02,Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results
2015-10-29,Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis
2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
2015-10-13,Alnylam Advances New Innovations In RNAi Therapeutics
2015-10-08,Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-10-07,Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock
2015-10-01,Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe
2015-09-28,Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute
2015-09-28,Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-09-25,Alnylam Pharmaceuticals Becomes Oversold
2015-09-21,Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)
2015-09-15,Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias
2015-09-10,Alnylam To Webcast Presentations At Upcoming September Conferences
2015-09-09,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today
2015-08-30,(Graphic: Business Wire)
2015-08-21,Ratings Changes Today
2015-08-07,Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-06,Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)
2015-08-06,Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities
2015-08-05,Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results
2015-07-30,3 Stocks Pushing The Drugs Industry Downward
2015-07-27,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-07-20,Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
2015-07-17,Today's Stocks Driving Success For The Drugs Industry
2015-07-17,Faruqi & Faruqi, LLP Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) On Behalf Of Its Shareholders
2015-07-16,Alnylam To Reschedule First RNAi Roundtable Webcast
2015-07-06,Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series
2015-06-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2015-06-23,Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-06-12,Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today
2015-06-12,Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases
2015-06-10,Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
2015-06-08,Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
2015-06-05,Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2015-05-28,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2015-05-26,Ratings Changes Today
2015-05-26,4 Big Biotech Companies to Sell Now
2015-05-26,Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
2015-05-20,Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-05-17,Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-05-15,3 Health Care Stocks Nudging The Sector Higher
2015-05-07,Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings
2015-05-07,Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress
2015-05-07,Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva
2015-04-30,Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results
2015-04-29,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2015-04-21,Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-04-16,New Lifetime High For Alnylam Pharmaceuticals (ALNY)
2015-04-13,Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
